Mesenchymal stem cells for prevention and treatment of immune responses in transplantation
AssigneeOsiris Therapeutics, Inc.
InventorsKevin R. McIntosh, Joseph D. Mosca, Elena N. Klyushnenkova
Life of this patent
Estimating the term…
Abstract
A method of reducing an immune response to a transplant in a recipient by treating said recipient with an amount of mesenchymal stem cells effective to reduce or inhibit host rejection of the transplant. The mesenchymal stem cells can be administered before, at the same time as, or after the transplant. Also disclosed is a method of inducing a reduced immune response against a host by foreign tissue, i.e., graft versus host disease, by treatment with mesenchymal stem cells.
Claims25
A process for reducing an immune response of effector cells against an alloantigen, comprising contacting effector cells with a supernatant of mesenchymal stem cells in an amount effective to reduce an immune response against an alloantigen whereby said effector cells upon contact with an alloantigen have a reduced immune response against said alloantigen.
A process for treating a transplant recipient to reduce in said recipient an immune response of effector cells against an alloantigen to the effector cells, comprising:
- transplanting to a transplant recipient a transplant treated with a supernatant of mesenchymal stem cells in an amount effective to reduce an immune response of effector cells against an alloantigen to the effector cells, whereby in the transplant recipient the effector cells have a reduced immune response against the alloantigen.
A process for treating a transplant recipient to reduce in said recipient an immune response of effector cells against an alloantigen to the effector cells, comprising:
- administering to a transplant recipient a supernatant of a mesenchymal stem cells in an amount effective to reduce an immune response of effector cells against an alloantigen to the effector cells, whereby in the transplant recipient the effector cells have a reduced immune response against the alloantigen.
A process of treating a transplant recipient for graft versus host disease, comprising treating the recipient of a donor transplant with a supernatant from a mesenchymal stem cell culture in an amount effective to reduce an immune response against the recipient by the transplant.
Dependencies are inferred from the claim text.